The guidance raise signals improving GLP-1 demand trends, but the 0% to -6% CER range still allows for a year-over-decline. Monitor the August 5 conference call for details on GLP-1 product mix, pricing, and whether the impairment of monlunabant signals a broader pipeline reset. The non-adjusted midpoint of 5% sales growth provides a more constructive baseline for near-term sentiment.
Price Chart
Executive Summary
Novo Nordisk raised its full-year 2026 adjusted sales and operating profit guidance ranges from -4% to -12% to 0% to -6% at CER, driven by increased GLP-1 product sales expectations. Q2 2026 adjusted sales grew 7% at CER to DKK 78,488 million and adjusted operating profit grew 11% at CER to DKK 33,389 million, though results include DKK 6.3 billion in non-cash impairment charges on pipeline assets including monlunabant. The improved guidance narrows the range but still implies potential year-over-year decline, while the non-adjusted midpoint of 5% sales and 12% operating profit growth suggests underlying operational strength that partially offsets the impairment noise.
Key Facts
- Q2 2026 adjusted sales: DKK 78,488 million, +7% at CER
- Q2 2026 adjusted operating profit: DKK 33,389 million, +11% at CER
- FY 2026 adjusted sales growth guidance raised to 0% to -6% at CER (from -4% to -12%)
- FY 2026 adjusted operating profit growth guidance raised to 0% to -6% at CER (from -4% to -12%)
- Includes DKK 6.3 billion non-recurring, non-cash impairment charges on intangible pipeline assets, including DKK 4.0 billion for monlunabant
- Non-adjusted midpoint of FY 2026 guidance: 5% sales growth, 12% operating profit growth at CER
Financial Impact
Guidance raised by ~6 percentage points at midpoint; Q2 adjusted operating profit of DKK 33.4B on sales of DKK 78.5B implies ~42.5% margin; DKK 6.3B impairment charge is non-cash but reduces reported net income
Risk Factors
- FY 2026 guidance still allows for 0% to -6% sales decline at CER, implying potential year-over-year contraction
- DKK 6.3 billion impairment charge on pipeline assets, including monlunabant, raises questions about R&D pipeline value
- Non-adjusted results include provision reversals from the 340B Drug Pricing Program, which may not recur
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005184 |
| Document: 0001171843-26-005184-index-headers.html | 0001171843-26-005184 |
| Document: 0001171843-26-005184-index.html | 0001171843-26-005184 |
| Document: 0001171843-26-005184.txt | 0001171843-26-005184 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $39.00 | awaiting T+20 | — | $38.73 (−0.68%) |
Oct 19, 2026 8d ago | 6-K | $38.42 | awaiting T+20 | — | $38.73 (+0.81%) |
Oct 13, 2026 14d ago | 6-K | $38.06 | awaiting T+20 | — | $38.73 (+1.76%) |
Oct 6, 2026 21d ago | 6-K | $37.53 | awaiting T+20 | — | $38.73 (+3.20%) |
Sep 28, 2026 29d ago | 6-K | $38.71 $38.95 | ▲ +0.61% | ▲ +0.64% | $38.73 (+0.05%) |
Sep 23, 2026 4w ago | Court Ruling | $38.62 $39.43 | ▲ +2.10% | ▲ +2.52% | $38.73 (+0.28%) |
Sep 21, 2026 5w ago | 6-K | $39.80 $38.42 | ▼ −3.47% | ▼ −2.56% | $38.73 (−2.69%) |
Sep 17, 2026 5w ago | 6-K | $43.19 $39.22 | ▼ −9.19% | ▼ −10.40% | $38.73 (−10.33%) |
Sep 15, 2026 6w ago | 6-K | $42.53 $38.06 | ▼ −10.51% | ▼ −13.23% | $38.73 (−8.93%) |
Sep 9, 2026 6w ago | 6-K | $44.56 $38.26 | ▼ −14.14% | ▼ −16.08% | $38.73 (−13.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers